HYPO-RT-PC Study Reveals Significant Gaps Between Patient and Clinician Symptom Reporting / Bowel Toxicity, clinical research ...
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) ("Karyopharm" or the "Company"), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that abstracts from two of its ...
When CAR-T is recommended, when is the best time to collect cells?When the treatment known as CAR-T is recommended, the first ...
A new study explores agentic AI for detecting and characterizing immune-related adverse events from clinical notes, ...
A multi-phase Nature Cancer study found that an agentic AI system detected immune-related adverse events in clinical notes ...
A retrospective analysis of 127 patients found that only 5 percent-level few exceeded 20 Gy cumulative kidney dose after ...
Copyright: © 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. Offering late-line systemic ...
🧬2026년 10월 16일 업데이트｜NEJM 2026·제III상 ATOMIC 임상시험또 한 번 면역관문억제제가 해냈다🤤2026년 10월 8일, 미국 FDA는 3기 dMMR 결장암에 대한 수술 후 보조요법으로 아테졸리주맙(제품명: 티쎈트릭/주가이)과 화학요법의 병용을 승인했다.근거가 된 것은 712명을 대상으로 한 제III상 임상시험 'ATOMIC'이다.
Copyright: © 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
In evaluation of photographs from before and after the intervention, improvements in HFS-related skin symptoms were observed in 31 patients (58.5%). All evaluated patients were also able to complete ...
LUT014 Gel Provides a Statistically Significant Benefit Over Placebo for the Treatment of Acneiform Rash Associated With Cetuximab or Panitumumab Therapy For Patients With Advanced Colorectal Cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results